Annals of Oncology Advance Access originally published online on May 3, 2006
Annals of Oncology 2006 17(6):909-913; doi:10.1093/annonc/mdl049
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2006 European Society for Medical Oncology
Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: a retrospective analysis of a uniformly-treated patient population
Lymphoma Service, Memorial Sloan-Kettering Cancer Center, New York, USA
* Correspondence to: Dr A. D. Zelenetz, Lymphoma Service, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA. Tel: +1 212–639–2656; Fax: +1 212–717–3036; E-mail: a-zelenetz{at}ski.mskcc.org
Background: Approximately one-third of the patients with relapsed aggressive non-Hodgkin's lymphoma (NHL) are cured by second-line chemotherapy followed by high-dose consolidation. The age-adjusted international prognostic index determined at the time of relapse (sAAIPI) predicts outcome in relapsed diffuse large B-cell lymphoma, suggesting that the success of salvage therapy could be enhanced by early relapse detection. This study evaluated the role of surveillance imaging in detection of relapsed disease and its impact on outcome of salvage treatment.
Patients and methods: One hundred and eight patients with relapsed aggressive NHL were treated with ICE-based second-line chemotherapy. Relapses were categorized as detected by imaging, examination, or patient-reported symptoms.
Results: Twenty per cent of relapses were detected by routine imaging while 80% were identified by reported symptoms or abnormalities on exam. Patients were 4.1 times (95% CI: 1.7–10.2) more likely to have low risk disease if relapse was diagnosed by routine imaging (group 1) compared with those diagnosed by reported symptoms or physical findings (group 2). Median overall 5-year survival for group 1 versus group 2 was 54% and 43% respectively (P = 0.13).
Conclusion: These results suggest that routine surveillance imaging can identify a population of patients with a more favorable outcome based on the sAAIPI.
Key words: lymphoma, relapse, surveillance imaging, follow-up
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  P. Seam, M. E. Juweid, and B. D. Cheson The role of FDG-PET scans in patients with lymphoma Blood, November 15, 2007; 110(10): 3507 - 3516. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. O. Armitage How I treat patients with diffuse large B-cell lymphoma Blood, July 1, 2007; 110(1): 29 - 36. [Full Text] [PDF]
|
|
|
|
 |
|
 B. D. Cheson, B. Pfistner, M. E. Juweid, R. D. Gascoyne, L. Specht, S. J. Horning, B. Coiffier, R. I. Fisher, A. Hagenbeek, E. Zucca, et al. Revised Response Criteria for Malignant Lymphoma J. Clin. Oncol., February 10, 2007; 25(5): 579 - 586. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. O. Armitage and F. R. Loberiza Is there a place for routine imaging for patients in complete remission from aggressive lymphoma? Ann. Onc., June 1, 2006; 17(6): 883 - 884. [Full Text] [PDF]
|
|